Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 8.53% and Operating profit at 2.01% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 5.60% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 8.53% and Operating profit at 2.01% over the last 5 years
3
Flat results in Jun 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,131 Million (Small Cap)
31.00
NA
1.89%
0.79
5.68%
1.78
Revenue and Profits:
Net Sales:
759 Million
(Quarterly Results - Jun 2025)
Net Profit:
86 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.3%
0%
-12.3%
6 Months
-5.31%
0%
-5.31%
1 Year
28.39%
0%
28.39%
2 Years
20.24%
0%
20.24%
3 Years
10.79%
0%
10.79%
4 Years
6.13%
0%
6.13%
5 Years
-0.66%
0%
-0.66%
Jinhe Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.53%
EBIT Growth (5y)
2.01%
EBIT to Interest (avg)
2.82
Debt to EBITDA (avg)
4.17
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.49
Tax Ratio
17.54%
Dividend Payout Ratio
74.79%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.63%
ROE (avg)
5.60%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
1.78
EV to EBIT
28.71
EV to EBITDA
13.83
EV to Capital Employed
1.44
EV to Sales
2.23
PEG Ratio
0.66
Dividend Yield
1.89%
ROCE (Latest)
5.00%
ROE (Latest)
5.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
758.60
619.30
22.49%
Operating Profit (PBDIT) excl Other Income
173.80
136.10
27.70%
Interest
22.90
22.10
3.62%
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
86.20
51.80
66.41%
Operating Profit Margin (Excl OI)
149.90%
122.90%
2.70%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 22.49% vs -12.52% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 66.41% vs 280.49% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,353.00
2,159.50
8.96%
Operating Profit (PBDIT) excl Other Income
384.30
330.70
16.21%
Interest
82.10
63.00
30.32%
Exceptional Items
-39.70
-8.10
-390.12%
Consolidate Net Profit
84.30
94.40
-10.70%
Operating Profit Margin (Excl OI)
78.90%
69.40%
0.95%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.96% vs 2.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -10.70% vs -20.07% in Dec 2023
About Jinhe Biotechnology Co., Ltd. 
Jinhe Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






